JP2015503608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503608A5 JP2015503608A5 JP2014551706A JP2014551706A JP2015503608A5 JP 2015503608 A5 JP2015503608 A5 JP 2015503608A5 JP 2014551706 A JP2014551706 A JP 2014551706A JP 2014551706 A JP2014551706 A JP 2014551706A JP 2015503608 A5 JP2015503608 A5 JP 2015503608A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- rnai agent
- beta
- composition
- catenin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 108091030071 RNAI Proteins 0.000 claims 18
- 230000009368 gene silencing by RNA Effects 0.000 claims 18
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 230000000692 anti-sense effect Effects 0.000 claims 12
- 102000015735 Beta-catenin Human genes 0.000 claims 11
- 108060000903 Beta-catenin Proteins 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 claims 4
- 108091081021 Sense strand Proteins 0.000 claims 4
- 206010052428 Wound Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 108010067316 Catenins Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 208000000172 Medulloblastoma Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000004210 Pressure Ulcer Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000010932 epithelial neoplasm Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 201000005290 uterine carcinosarcoma Diseases 0.000 claims 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 2
- 102000016362 Catenins Human genes 0.000 claims 2
- 229920002101 Chitin Polymers 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- -1 Epi-Freedelanol Natural products 0.000 claims 2
- JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 claims 2
- 229920001202 Inulin Polymers 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 229920001218 Pullulan Polymers 0.000 claims 2
- 239000004373 Pullulan Substances 0.000 claims 2
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003431 cross linking reagent Substances 0.000 claims 2
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 claims 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 claims 2
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 claims 2
- MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229960003160 hyaluronic acid Drugs 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 2
- 229940029339 inulin Drugs 0.000 claims 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 150000002634 lipophilic molecules Chemical class 0.000 claims 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 2
- 229920005615 natural polymer Polymers 0.000 claims 2
- 229920000768 polyamine Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 235000019423 pullulan Nutrition 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 125000006853 reporter group Chemical group 0.000 claims 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 150000003505 terpenes Chemical class 0.000 claims 2
- 235000007586 terpenes Nutrition 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 150000003648 triterpenes Chemical class 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261584530P | 2012-01-09 | 2012-01-09 | |
| US61/584,530 | 2012-01-09 | ||
| US201261598530P | 2012-02-14 | 2012-02-14 | |
| US61/598,530 | 2012-02-14 | ||
| PCT/IB2013/050159 WO2013105022A2 (en) | 2012-01-09 | 2013-01-08 | Organic compositions to treat beta-catenin-related diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503608A JP2015503608A (ja) | 2015-02-02 |
| JP2015503608A5 true JP2015503608A5 (enExample) | 2016-03-03 |
| JP6158833B2 JP6158833B2 (ja) | 2017-07-05 |
Family
ID=47720548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551706A Active JP6158833B2 (ja) | 2012-01-09 | 2013-01-08 | ベータ−カテニン関連疾患を処置するための有機組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10023862B2 (enExample) |
| EP (1) | EP2802658A2 (enExample) |
| JP (1) | JP6158833B2 (enExample) |
| CN (1) | CN104302768A (enExample) |
| AU (1) | AU2013208720A1 (enExample) |
| BR (1) | BR112014016870A2 (enExample) |
| CA (1) | CA2860676A1 (enExample) |
| HK (1) | HK1205758A1 (enExample) |
| WO (1) | WO2013105022A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015162172A2 (en) * | 2014-04-22 | 2015-10-29 | Medizinische Hochschule Hannover | Incrnas for therapy and diagnosis of angiogenesis |
| WO2017160983A1 (en) | 2016-03-16 | 2017-09-21 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of a beta-catenin-associated disease or disorder |
| US11185553B2 (en) * | 2016-10-31 | 2021-11-30 | Samsung Life Public Welfare Foundation | Pharmaceutical composition for preventing or treating ischemic-reperfusion injury comprising bile acids |
| US11813280B2 (en) | 2018-01-05 | 2023-11-14 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
| EP3752614A4 (en) * | 2018-02-14 | 2021-11-10 | Deep Genomics Incorporated | OLIGONUCLEOTIDE THERAPY FOR WILSON'S DISEASE |
| CN111500694B (zh) | 2019-01-31 | 2023-02-24 | 中国科学院脑科学与智能技术卓越创新中心 | Baz2b基因作为靶点在缓解衰老中的应用 |
| TW202130809A (zh) * | 2019-10-29 | 2021-08-16 | 美商愛羅海德製藥公司 | 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法 |
| WO2022125725A1 (en) | 2020-12-09 | 2022-06-16 | The Regents Of The University Of Michigan | Compositions and methods for treating wnt-driven cancer |
| WO2022187263A2 (en) * | 2021-03-01 | 2022-09-09 | Steadman Philippon Research Institute | Mcm for gene therapy to activate wnt pathway |
| TW202325312A (zh) * | 2021-07-23 | 2023-07-01 | 美商艾拉倫製藥股份有限公司 | β－鏈蛋白（ＣＴＮＮＢ１）ｉＲＮＡ組成物及其使用方法 |
| WO2025090541A1 (en) * | 2023-10-25 | 2025-05-01 | The Regents Of The University Of California | Covalent degraders of oncogenic transcription factors |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696561B1 (en) | 1909-07-09 | 2004-02-24 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| KR20010042069A (ko) | 1998-03-20 | 2001-05-25 | 베니텍 오스트레일리아 리미티드 | 유전자 발현 조절방법 |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| BR0009884A (pt) | 1999-04-21 | 2002-01-08 | American Home Prod | Processos e composições para a inibição da função das sequências de polinucleotìdeos |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| CA2378653A1 (en) | 1999-07-09 | 2001-01-18 | American Home Products Corporation | Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| RU2164944C1 (ru) | 1999-12-09 | 2001-04-10 | Институт молекулярной биологии им. В.А. Энгельгардта РАН | Способ изменения генетических свойств организма |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| CA2403162A1 (en) | 2000-03-17 | 2001-09-27 | Benitec Australia Ltd. | Genetic silencing |
| EP1268535B1 (de) | 2000-03-22 | 2013-05-22 | Sanofi-Aventis Deutschland GmbH | Parkin aus c. elegans, nematode, der eine aberrante oder fehlende expression eines parkingens aufweist, und verwendungen davon |
| PT1309726E (pt) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Mediadores de interferência por rna específicos de sequência de rna |
| CA2410947A1 (en) | 2000-05-30 | 2001-12-06 | Johnson & Johnson Research Pty Limited | Methods for mediating gene suppresion by using factors that enhance rnai |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| CA2416685C (en) | 2000-07-19 | 2008-10-07 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| US20030166064A1 (en) | 2000-08-03 | 2003-09-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of colon cancer |
| KR100909681B1 (ko) | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| EP1424998B1 (en) | 2001-08-16 | 2010-05-26 | The Trustees of The University of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| WO2003064625A2 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
| SI1482924T1 (sl) | 2002-03-05 | 2008-12-31 | Merck Frosst Canada Ltd | Katepsin cistein proteazni inhibitorji |
| WO2003076424A1 (en) | 2002-03-08 | 2003-09-18 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| DE60330227D1 (de) | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| DE60334618D1 (de) | 2002-06-28 | 2010-12-02 | Protiva Biotherapeutics Inc | Verfahren und vorrichtung zur herstellung von liposomen |
| KR20050084607A (ko) | 2002-09-28 | 2005-08-26 | 매사추세츠 인스티튜트 오브 테크놀로지 | 인플루엔자 치료제 |
| US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| CA2506714A1 (en) | 2002-11-26 | 2004-06-10 | University Of Massachusetts | Delivery of sirnas |
| US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
| AU2004220556B2 (en) | 2003-03-07 | 2009-05-07 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
| JP4912873B2 (ja) * | 2003-04-09 | 2012-04-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ｉＲＮＡ複合体 |
| CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| CN101291653B (zh) | 2003-07-16 | 2012-06-27 | 普洛体维生物治疗公司 | 脂质包封的干扰rna |
| NZ545360A (en) | 2003-08-28 | 2009-06-26 | Novartis Ag | Interfering RNA duplex having blunt-ends and 3'-modifications |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| AU2005248147A1 (en) | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| KR20170001725A (ko) | 2004-09-02 | 2017-01-04 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| WO2006031977A2 (en) | 2004-09-13 | 2006-03-23 | The Regents Of The University Of California | Inhibition of pancreatic cancer cell growth |
| EP1851340B1 (en) | 2005-02-10 | 2013-01-30 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of diagnosing and treating cancer using b-catenin splice variants |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| ES2481402T3 (es) | 2005-07-21 | 2014-07-30 | Ardea Biosciences, Inc. | Inhibidores de N-(arilamino)sulfonamida de MEK |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| US20100105134A1 (en) | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2008109369A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| WO2008132234A2 (en) * | 2007-05-01 | 2008-11-06 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of beta-catenin |
| US8314227B2 (en) | 2007-05-22 | 2012-11-20 | Marina Biotech, Inc. | Hydroxymethyl substituted RNA oligonucleotides and RNA complexes |
| US20080311081A1 (en) | 2007-06-15 | 2008-12-18 | Johannes Fruehauf | Bacteria mediated gene silencing |
| CA2699202C (en) | 2007-09-12 | 2016-09-27 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| EP2214675B1 (en) | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US20100267626A1 (en) * | 2007-11-05 | 2010-10-21 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| EP2238251B1 (en) | 2007-12-27 | 2015-02-11 | Protiva Biotherapeutics Inc. | Silencing of polo-like kinase expression using interfering rna |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| TWI455944B (zh) * | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
| EP2266550A1 (en) | 2009-06-15 | 2010-12-29 | Institut Curie | Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders |
| CA2677068A1 (en) | 2009-09-01 | 2011-03-01 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| CN102573914B (zh) | 2009-10-16 | 2016-06-29 | 大学健康网络 | 卟啉纳米囊泡 |
| CA2784783C (en) * | 2009-12-18 | 2021-07-20 | Novartis Ag | Organic compositions to treat hsf1-related diseases |
| DK3587579T3 (da) | 2010-07-06 | 2021-04-26 | Dicerna Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna |
| CN107090456B (zh) * | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
-
2013
- 2013-01-08 CA CA2860676A patent/CA2860676A1/en not_active Abandoned
- 2013-01-08 EP EP13704633.0A patent/EP2802658A2/en active Pending
- 2013-01-08 CN CN201380013297.9A patent/CN104302768A/zh active Pending
- 2013-01-08 JP JP2014551706A patent/JP6158833B2/ja active Active
- 2013-01-08 WO PCT/IB2013/050159 patent/WO2013105022A2/en not_active Ceased
- 2013-01-08 AU AU2013208720A patent/AU2013208720A1/en not_active Abandoned
- 2013-01-08 HK HK15106407.7A patent/HK1205758A1/xx unknown
- 2013-01-08 BR BR112014016870A patent/BR112014016870A2/pt not_active IP Right Cessation
- 2013-01-08 US US14/371,131 patent/US10023862B2/en active Active
-
2018
- 2018-06-13 US US16/007,517 patent/US20180282728A1/en not_active Abandoned
-
2024
- 2024-11-07 US US18/939,814 patent/US20250270555A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503608A5 (enExample) | ||
| JP2014525435A5 (enExample) | ||
| JP2015517466A5 (enExample) | ||
| AU2013208720A1 (en) | RNAi agents to treat Beta-Catenin related diseases | |
| JP2016511256A5 (enExample) | ||
| JP4788774B2 (ja) | 抗癌剤の併用による癌治療方法 | |
| JP2023093644A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| Lai et al. | Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras | |
| Huang et al. | Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase | |
| CN107108686B (zh) | 用于恶性肿瘤的rna干扰组合物和方法 | |
| Li et al. | Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure | |
| Gao et al. | Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells | |
| JP2013514321A5 (enExample) | ||
| AR079494A1 (es) | Composiciones organicas para tratar las enfermedades relacionadas con el factor de choque por calor 1 hsf1 | |
| Roca-Alonso et al. | Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms? | |
| JP2018536689A5 (enExample) | ||
| JP2018512060A5 (enExample) | ||
| MX348817B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| Sun et al. | Abiraterone acetate for metastatic castration‐resistant prostate cancer after docetaxel failure: A randomized, double‐blind, placebo‐controlled phase 3 bridging study | |
| JP2013525332A5 (enExample) | ||
| RU2013145551A (ru) | Комбинация олигонуклеотида анти-кластерина с антагонистом рецептора андрогена для лечения рака предстательной железы | |
| WO2016100858A1 (en) | Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype | |
| Lang et al. | Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer | |
| Abate et al. | Self-assembling nanoparticles for delivery of miR-603 and miR-221 in glioblastoma as a new strategy to overcome resistance to temozolomide |